Mammalian target of rapamycin in chronic liver disease and the potential for therapeutic manipulation.
2/5 보강
TL;DR
A narrative review summarises the role of mTOR in the healthy liver, its dysregulation across common aetiologies of CLD, and its role in HCC and underscores a clear unmet need for well-designed human clinical trials to specifically assess mTOR inhibitors as potential anti-fibrotic therapies.
OpenAlex 토픽 ·
PI3K/AKT/mTOR signaling in cancer
Liver physiology and pathology
Tuberous Sclerosis Complex Research
A narrative review summarises the role of mTOR in the healthy liver, its dysregulation across common aetiologies of CLD, and its role in HCC and underscores a clear unmet need for well-designed human
APA
Pramudi Wijayasiri, Mamatha Bhat, Aloysious Aravinthan (2026). Mammalian target of rapamycin in chronic liver disease and the potential for therapeutic manipulation.. Experimental gerontology, 217, 113105. https://doi.org/10.1016/j.exger.2026.113105
MLA
Pramudi Wijayasiri, et al.. "Mammalian target of rapamycin in chronic liver disease and the potential for therapeutic manipulation.." Experimental gerontology, vol. 217, 2026, pp. 113105.
PMID
41864372 ↗
Abstract 한글 요약
Chronic Liver Disease (CLD) represents a growing epidemic in the Western world, yet treatment options that effectively slow its progression remain limited. Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus (also known as rapamycin), have been proposed as potential antifibrotic agents over the past decade; however, their role in chronic liver disease remains underexplored. mTOR is a protein kinase integral to a key cellular pathway, which is essential for normal liver physiology but is also implicated in the pathogenesis of CLD and hepatocellular carcinoma (HCC). This narrative review summarises the role of mTOR in the healthy liver, its dysregulation across common aetiologies of CLD, and its role in HCC. An electronic literature search of Ovid MEDLINE was conducted from database inception to 2025 to identify studies evaluating the role of MTOR in CLD. The review underscores a clear unmet need for well-designed human clinical trials to specifically assess mTOR inhibitors as potential anti-fibrotic therapies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.